Spots Global Cancer Trial Database for Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients
Official Title: A Clinical Study Of Enadenotucirev Administered by Sub-Acute Fractionated Intravenous Injection: Dose Escalation in Metastatic Epithelial Solid Tumours and Randomised Controlled Trial in Metastatic Colorectal Cancer
Study ID: NCT02028442
Interventions
Study Description
Brief Summary: This is a multicentre, open-label, Phase I/II study of enadenotucirev in patients with either solid tumour of epithelial origin not responding to standard therapy or for whom no standard treatment exists (Phase I dose escalation stage Single cycle), mCRC not responding to standard therapy (Phase I dose escalation Repeat cycle cohort expansion stage ), mCRC not responding to standard therapy or advanced or metastatic bladder cancer not candidate for chemotherapy (Phase Ib) or mCRC in stable disease or partial response after 3-4 months of first line standard of care chemotherapy (Phase II).
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
GZA ziekenhuizen campus Sint-Augustinus, Wilrijk, Antwerp, Belgium
Cliniques Universitaires St Luc, Bruxelles, , Belgium
Ghent University Hospital, Ghent, , Belgium
Institut Catala d Oncologica, Barcelona, , Spain
START - Hospital Universitario Madrid Sanchinarrio, Madrid, , Spain
Hospital Universitario Virgen del Rocio (HUVR), Seville, , Spain
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
